Multiple myeloma medicines: understanding the prescription and arranging treatment in China

A myeloma prescription often contains several anticancer medicines, preventive medicines and a steroid, with different treatment days for each. Understanding that schedule matters as much as recognizing the newest drug name. The appropriate combination depends on the phase of illness, previous resistance, kidney function, fitness and the services available for monitoring. Information below was checked in September 2026. It explains decisions to discuss with the hematology team; it is not a dosing schedule for an individual patient.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Proteasome inhibitors, immunomodulatory medicines and antibodies against CD38 attack myeloma through different mechanisms and frequently appear together. Other treatments include conventional chemotherapy, nuclear export inhibition, antibody–drug conjugates and therapies that redirect T cells. A newer mechanism does not make every older medicine unnecessary. A maintenance prescription also has a different purpose from a combination intended to regain control after relapse. The National Cancer Institute's treatment review describes these treatment categories and their roles.
In August 2026, the US FDA granted accelerated approval to iberdomide with subcutaneous daratumumab/hyaluronidase and dexamethasone for adults previously treated with at least one line including a proteasome inhibitor and an immunomodulatory drug. The supporting study excluded patients refractory to anti-CD38 therapy or bortezomib. Its accelerated-approval endpoint was MRD-negative complete response; that is not equivalent to mature proof of an overall-survival benefit in every resistant population. The FDA decision also identifies embryo-fetal toxicity, thrombosis, neutropenia and infection among material risks. Chinese authorization and access require separate verification.
The Chinese team should verify current national indications, the formulation on its formulary and the patient's eligibility. The National Health Commission's 2025 anticancer medicine guidance, released in January 2026, is a useful reference but does not replace subsequent updates. Overseas or investigational uses described in a document should not automatically be interpreted as Chinese approvals. Hospital supply, reimbursement and international-patient billing also need individual confirmation.

Quick answer

Full guide

Read the complete regimen, including the medicines outside its abbreviation

Proteasome inhibitors, immunomodulatory medicines and antibodies against CD38 attack myeloma through different mechanisms and frequently appear together. Other treatments include conventional chemotherapy, nuclear export inhibition, antibody–drug conjugates and therapies that redirect T cells. A newer mechanism does not make every older medicine unnecessary. A maintenance prescription also has a different purpose from a combination intended to regain control after relapse. The National Cancer Institute's treatment review describes these treatment categories and their roles.

Ask the prescriber to identify the purpose of every item on the medication list. Antiviral prophylaxis, clot prevention, bone protection and anti-nausea treatment may not appear in the familiar regimen acronym, yet they may be necessary for that regimen to be delivered safely. A calendar should show the actual treatment dates, planned breaks and blood-test appointments. Weekly or intermittent instructions are particularly easy to misunderstand when several languages or different hospital discharge documents are involved.

Record the generic name as well as the brand. The intravenous and subcutaneous versions of an antibody, or products with different combination partners, cannot be treated as interchangeable on the basis of a similar name. A prescription change should be confirmed by the team responsible for the whole regimen, including the supportive medicines.

Proteasome inhibitors require different safety discussions

Bortezomib can cause peripheral neuropathy. Tell the team about numbness, burning pain or altered balance already present before treatment, including symptoms related to diabetes. New difficulty fastening buttons, handling cutlery or walking should be reported early; the clinician may need to change the dose, route or schedule. Waiting until symptoms are severe can make recovery more difficult. The need for antiviral prevention against shingles should also be discussed. These issues are described in the bortezomib prescribing information.

Carfilzomib belongs to the same broad drug class but has a different safety profile. Cardiac toxicity, hypertension, breathlessness and acute kidney injury are important concerns. A history of heart failure, poorly controlled blood pressure, swelling or a recent change in exercise tolerance should be reviewed before treatment. Hydration must balance treatment requirements against the risk of fluid overload; patients should not attempt to replace the prescribed plan by drinking large amounts independently. The carfilzomib label explains the relevant warnings and monitoring.

An oral proteasome inhibitor may reduce some clinic visits, but convenience is only one part of selection. Its evidence, approved setting and combination partners still need to fit the patient's disease. Decisions about continuing treatment during an infection or a new organ problem should come from the treating service, rather than from comparison with another patient's experience.

Oral immunomodulatory medicines need active supervision

Lenalidomide and pomalidomide are used in various combinations and treatment phases. With lenalidomide, kidney function is particularly important to prescribing. A dose chosen before renal recovery or deterioration may need reassessment. Blood counts, thrombosis risk and embryo-fetal toxicity also require attention. The lenalidomide prescribing information sets out these risks and the need for renal adjustment.

Bring current kidney results and the dialysis schedule, where applicable. Tell the clinician about missed doses rather than trying to compensate with extra tablets. Dose reduction for toxicity can be a deliberate way to keep an effective treatment usable; it should not automatically be interpreted as treatment failure.

Clot prevention must be individualized. Previous thrombosis, mobility, steroid exposure, platelet count, kidney function and bleeding history affect the choice. A patient should not start aspirin because another patient receives it, or stop an anticoagulant solely because bruises have appeared. People who could become pregnant and their partners need the exact product's pregnancy-testing and contraception requirements, including the period after treatment. Instructions for one medicine should not be assumed to apply to every medicine in the class.

Anti-CD38 treatment requires communication with the laboratory

Daratumumab and other anti-CD38 therapies are used with several myeloma regimens. The formulation, approved combination and observation requirements should be checked for the product actually being supplied. The team also needs to arrange appropriate premedication, reaction monitoring and infection assessment. Reduced injection time does not remove the need for those preparations.

Daratumumab can interfere with blood compatibility testing. Providing the transfusion laboratory with the treatment history and obtaining relevant baseline blood-group information can prevent confusion if transfusion becomes urgent. Keep the treatment name accessible when attending a different emergency department. Separately, the therapeutic antibody can complicate interpretation of small monoclonal protein bands. A faint band should be assessed alongside treatment dates and the laboratory method, rather than immediately labeled relapse. An original study of daratumumab immunofixation interference explains this analytical problem.

These are practical reasons to keep laboratory and medication records together. A visiting patient may receive treatment in one country and have blood tests in another. The second laboratory needs to know what was administered even when the patient feels well and the previous discharge summary describes a good response.

Recent approvals must be read with their population and endpoint

In August 2026, the US FDA granted accelerated approval to iberdomide with subcutaneous daratumumab/hyaluronidase and dexamethasone for adults previously treated with at least one line including a proteasome inhibitor and an immunomodulatory drug. The supporting study excluded patients refractory to anti-CD38 therapy or bortezomib. Its accelerated-approval endpoint was MRD-negative complete response; that is not equivalent to mature proof of an overall-survival benefit in every resistant population. The FDA decision also identifies embryo-fetal toxicity, thrombosis, neutropenia and infection among material risks. Chinese authorization and access require separate verification.

Selinexor, an oral nuclear export inhibitor, raises a different set of practical concerns. Nausea, poor appetite, weight loss, low platelets and low sodium can interrupt treatment. Antiemetic preparation, nutritional assessment and electrolyte monitoring should therefore be part of the plan, rather than added only after a patient becomes unwell. The selinexor label provides the basis for this monitoring. Persistent vomiting, marked drowsiness or confusion needs medical assessment; self-treatment with salt or excessive fluids may be inappropriate.

The useful question about a new medicine is whether its studied population resembles the person considering it. “Previously exposed” and “refractory during treatment” are not synonyms. Preserve the dates, response and reason for stopping each previous regimen, because these details can be more decisive than the total number of medicines tried.

Bispecific antibodies need both early observation and continuing infection care

Bispecific antibodies directed at BCMA or GPRC5D bring T cells into contact with myeloma cells. Their initial step-up schedules and observation requirements are intended to detect cytokine release syndrome and neurological toxicity promptly. Fever, low blood pressure, breathing difficulty or changes in speech, behavior or awareness should be assessed through the treatment team's emergency pathway. Patients should not assume that a fever after an injection is harmless because a similar reaction occurred with a previous drug.

In March 2026, the FDA approved teclistamab with daratumumab/hyaluronidase for eligible relapsed or refractory myeloma after at least one previous line. The monotherapy indication has different prior-treatment requirements. An earlier-line combination approval does not automatically move every use of the medicine to the same setting. The FDA teclistamab announcement also highlights infection, low immunoglobulins and neurological toxicity. Those concerns can persist after the initial step-up period.

Talquetamab targets GPRC5D and can cause taste disturbance, dry mouth, skin and nail changes, swallowing difficulties and weight loss. Establishing a baseline weight and describing the usual diet helps the team recognize changes. A patient who can no longer tolerate previously acceptable food may need nutritional support and a treatment review, even if laboratory markers show a response. These distinctive effects are documented in the FDA talquetamab information.

Do not assume that different bispecific products have identical schedules, observation periods or restart rules after a treatment gap. Before international travel, the receiving service should confirm that it can deliver the exact next dose and manage the relevant complications. An appointment in a general infusion clinic may not provide the required specialist support.

Belantamab combinations require access to eye assessment

Historical news about withdrawal of US belantamab monotherapy does not describe all current uses. In October 2025, the FDA approved belantamab mafodotin with bortezomib and dexamethasone for eligible relapsed or refractory disease after at least two prior lines. Corneal toxicity and changes in vision are major treatment considerations. Eye examinations and dose interruption or modification can become part of the course. The FDA combination approval defines the population and ocular risks.

For someone who drives for work, lives alone or plans a short stay in China, possible visual impairment has consequences beyond the infusion appointment. Confirm where the eye examinations will occur, how results reach the hematologist and who can help if vision changes. Advice on contact lenses, eye drops and driving should follow the product-specific clinical plan. A drug's availability alone does not establish that its full monitoring pathway is available to a visiting patient.

Turn a Chinese prescription into a plan that can continue at home

The Chinese team should verify current national indications, the formulation on its formulary and the patient's eligibility. The National Health Commission's 2025 anticancer medicine guidance, released in January 2026, is a useful reference but does not replace subsequent updates. Overseas or investigational uses described in a document should not automatically be interpreted as Chinese approvals. Hospital supply, reimbursement and international-patient billing also need individual confirmation.

Bring a single list of prescription medicines, herbal products, supplements and recent vaccinations. Include allergies, start and stop dates, and the reason a medicine was discontinued. If treatment will continue after returning home, obtain agreement from the home hematologist before the first cycle about laboratory monitoring, prescribing responsibility and legal medicine supply. Sending a photograph of a package after the last Chinese appointment is too late to resolve a missing local treatment pathway.

Ask for a written calendar, the tests needed before each decision, and a contact route for unexpected symptoms. The financial estimate should cover a stated interval and include administration, blood and chemistry tests, infection prevention and any eye or cardiac assessments relevant to the chosen drugs. A reliable total cannot be supplied without a defined prescription and hospital quotation. The aim is a regimen the patient understands and can receive consistently, with a clear response when health or laboratory results change.